Indivior's shares soar 33 percent after U.S. court blocks sale of rival generic

Indivior Plc’s shares jumped more than 33 percent on Monday after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker’s bestselling opioid addiction treatment.